Alpha-v Integrins as Therapeutic Targets in Oncology

Integrins are heterodimeric cell adhesion receptors that mediate intercellular communication through cell-extracellular matrix interactions and cell-cell interactions. Integrins have been demonstrated to play a direct role in cancer progression, specifically in tumor cell survival, tumor angiogenesi...

Full description

Saved in:
Bibliographic Details
Published in:Cancer investigation 2007-10, Vol.25 (7), p.632-646
Main Authors: Nemeth, Jeffrey A., Nakada, Marian T., Trikha, M., Lang, Zhihui, Gordon, Michael S., Jayson, Gordon C., Corringham, Robert, Prabhakar, Uma, Davis, Hugh M., Beckman, Robert A.
Format: Article
Language:English
Subjects:
Adhesion
Angiogenesis
Angiogenesis Inhibitors - pharmacology
Animals
Anti-tumor
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bone Remodeling - drug effects
Clinical trials
Clinical Trials, Phase II as Topic
Humans
Integrin alphaV - chemistry
Integrin alphaV - physiology
Integrins
Neoplasm Metastasis
Neoplasms - drug therapy
Neoplasms - etiology
Signal Transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Integrins are heterodimeric cell adhesion receptors that mediate intercellular communication through cell-extracellular matrix interactions and cell-cell interactions. Integrins have been demonstrated to play a direct role in cancer progression, specifically in tumor cell survival, tumor angiogenesis, and metastasis. Therefore, agents targeted against integrin function have potential as effective anticancer therapies. Numerous anti-integrin agents, including monoclonal antibodies and small-molecule inhibitors, are in clinical development for the treatment of solid and hematologic tumors. This review focuses on the role of αv integrins in cancer progression, the current status of integrin-targeted agents in development, and strategies for the clinical development of anti-integrin therapies.
ISSN:0735-7907
1532-4192
DOI:10.1080/07357900701522638